Fundraising FoxOmega Funds
Venture capitalBoston · Seed–Late Stage · 19 people tracked
Find your way into Omega Funds
Sign up to see every warm intro you have to Omega Funds
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Omega Funds team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Team · 19 people
from public directories
Michael Powell is a venture advisor at Lantana Ranch with over four decades of experience in pharmaceutical development. He has been involved in the development of approximately 50 pharmaceutical products across roles at Syntex, Cytel, Genentech, Sofinnova Ventures, and Omega Funds, and has authored 90 papers and books on topics including vaccine adjuvants. Powell has served as an early investor in multiple biotech companies including Actelion, Seattle Genetics, and Bicara Therapeutics, and holds board positions at Washington University and various pharmaceutical industry organizations.
Noelle Hutchins is a Principal at Omega Funds focused on biotech venture capital investment. She has background in immunology and provides scientific strategy and advisory services to early-stage companies developing commercial innovations in healthcare.
Partner with over ten years of academic licensing and venture investing experience. Spent over six years on the investment team at Omega Funds and previously worked at MIT's Technology Licensing Office; holds a PhD in Biomedical Engineering from the University of Michigan.
Benjamin Youn is a biotechnology strategy and technical operations professional with over 15 years of experience spanning technical operations, drug substance development, and venture capital. He advises biotech leadership teams on CMC strategy, regulatory and manufacturing readiness, portfolio management, and capital allocation, and has led MSAT and biologics manufacturing teams in cGMP environments. His diligence work includes reviewing IND/BLA submissions, Module 3 CMC documentation, and CDMO networks across more than 50 biotech companies, and he holds an MBA from Wharton.
What they invest in
from 41 of 46 portfolio companiesBiotech ×36Healthtech ×20Medical Devices ×15Digital Health ×7Deep Tech ×6Longevity ×3AI & Machine Learning ×2Advanced Manufacturing ×1
HQs:United States×34Belgium×1Switzerland×1Colombia×1Norway×1
Investments · 46 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 42024 · 62023 · 32022 · 22021 · 62020 · 52019 · 12018 · 32017 · 12016 · 12014 · 238 dated
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSteven Russell(Chief Medical Officer)inMark Hopman(Chief Commercial Officer)in
Board seatFrancesco Draetta· per SEC Form D · $101.8M raise · filed Sep 2023
Co-investorsLifeSci Venture PartnersWellington ManagementRTW Investments L.P.Soleus Capital
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inINDERPAL SINGH(Executive Officer)inHella Kohlhof(Executive Officer)inPatrick Walsh(Executive Officer)Aron Stern(Executive Officer)
Board seatVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022
Co-investorsBayern Kapitalbmp VenturesFund+Pontifax Venture Capital
Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients.
BiotechHealthtechNew York, US
David Hung(Founder)inDavid Hanley(Chief Technical Operations Officer)inGary Hattersley(Chief Scientific Officer)inStacy Markel(Chief People Officer)inPhilippe Sauvage(Chief Financial Officer)inColleen Sjogren(Chief Commercial Officer)in
Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalVertex Ventures China
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
Board seatClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsBain Capital Life SciencesLumira VenturesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalAdvent Life Sciences+1 more
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.
Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRA Capital+6 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life Sciences+3 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)inRebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo Holdings+1 more
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.
BiotechHealthtechNew Haven, US
Thomas Sciascia(Executive Officer)Jennifer Good(Co-Founder, President and CEO)inThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)Lisa Delfini(Executive Officer)inWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in
Co-investorsAPERTURE Venture PartnersFrazier Life SciencesNew Enterprise Associates (NEA)Pivotal Life SciencesViking Global
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+5 more
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesTenmileAbingworthAlleyCorp+1 more
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsFrazier Life SciencesJeito CapitalNorwest Venture Partners
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Board seatOtello Stampacchia· per SEC Form D
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida Ventures+3 more
Spiro Medical is a clinical-stage medical device company developing neuromodulation therapies for severe, uncontrolled asthma and other respiratory conditions.
BiotechHealthtechMedical DevicesBelleair Bluffs, US
Rinda Sama(Executive Officer)in
BoardBrian Mooney(Director)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
Co-investorsAndera PartnersSupernova Invest
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)in
Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D
Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundForesite CapitalHillhouse Investment+1 more
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)inShane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)
BoardDuke Rohlen(Director)inJD Friedland(Director)
Board seatSaoussen Ben Halima· per SEC Form D
Co-investorsAPERTURE Venture PartnersBroadview VenturesCincyTechIntuitive VenturesJobsOhio VenturesAjax Health
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLC+2 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inAmra Demirovic(Chief Human Resources Officer)inNicole Hadas(Chief Legal Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalSofinnova VenturesAlexandriaB Capital+2 more
.jpeg){kind=logo}
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis Ventures
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inRandall Stanicky(Executive Officer)inAnthony Costello(Director)Bruce Robertson(Director)Douglas Langa(Director)
BoardAlex Zisson(Director)
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesRevelation Partners+5 more
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
BiotechSan Diego, US
John Hood(Co-Founder, Chief Executive Officer & Executive Chairman)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)Monal Mehta(Director)inMiguel de los Rios(Co-Founder & Chief Scientific Officer)in
Co-investorsFidelity InvestmentsLongitude Capital
Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development.
BiotechDeep TechMedical DevicesNiel, BE
Co-investorsFund+PMVBoehringer Ingelheim Venture FundEQT Life SciencesNovalis LifeSciencesPWV
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.
BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US
Christine Lemke(Executive Officer, Director)inDeborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein
BoardDavid Fleshman(Director)Rowan Chapman(Director)in
Co-investorsAsset Management CompanyB Capital GroupB4 CapitalCross Creek AdvisorsDementia Discovery FundFresco Capital+6 more
EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.
BiotechHealthtechHolborn, London
David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)
Co-investorsJeito CapitalSamsara BioCapitalSV Health Investors
FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.
BiotechDeep TechHealthtechBasel, CH
Tarig Bashir(Chief Executive Officer (CEO))inJens Würthner(Chief Medical Officer (CMO))Frank Zenke(Chief Scientific Officer (CSO))in
Co-investorsM VenturesNovartis Venture FundPfizer Venture Investments
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareWaltham, US
Micah K Johnson(Executive Officer, Director)Edward Adelson(Director)Kimo Johnson(Co-Founder & Chief Science Officer)inJanos Rohaly(Co-Founder & Chief Technology Officer)inWilliam J. Yost(Executive Officer, Director)Youssef Benmokhtar(Chief Executive Officer)in
Co-investorsAnzu PartnersScout VenturesScout Ventures
JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.
Digital HealthHealthtechMedical DevicesIrvine, US
Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)John Kilcoynein
.jpg)
BoardArnd Kaltofen(Director)in
Co-investorsAndera PartnersBain Capital Life SciencesRosetta Capital Ltd.VI PartnersAtlas VentureGimv+5 more
Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech InvestVida VenturesBlackRockCommodore Capital+2 more
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)
Co-investorsSanofi VenturesAtlas VentureHatteras Venture PartnersLilly VenturesRoche Venture Fund
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsBrandon CapitalCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM Ventures+1 more
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)inRafael Casabianca
Co-investorsNovartis Venture FundY CombinatorDigitalis VenturesDroia VenturesForbionGlilot Capital Partners+7 more
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
BoardGeoffrey von Maltzahn(Director)in
Co-investorsAmerican Family VenturesARCH Venture PartnersCatalytic Impact FoundationF-Prime CapitalFlagship PioneeringGV (Google Ventures)+8 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNextech InvestNexTech VenturesOrbiMedPontifax Venture Capital+2 more
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)
Co-investorsAvoro Capital AdvisorsOrbiMedOUP (Osage University Partners)Pontifax Venture CapitalCasdin Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Caldera Therapeutics, Inc.ESSA PharmaIkena Oncology, Inc.Morphic Holding, Inc.TheRas, Inc.Aerium TherapeuticsAndrew AllianceCallio TherapeuticsLexeo Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 12
10 IPOs · 2 acquisitions · showing 11Beta Bionics, IncNASDAQ: BBNXImmunicNASDAQ: IMUXNuvation BioNYSE: NUVBX4 PharmaNASDAQ: XFORBicara TherapeuticsNASDAQ: BCAXGossamer BioNASDAQ: GOSSInvivydNASDAQ: IVVDSpruce BiosciencesNASDAQ: SPRBTrevi TherapeuticsNASDAQ: TRVIUpstream BioNASDAQ: UPBEyebiotechacq. by Merck
Portfolio news
latest coverage across their companiesInvivyd · investors.invivyd.com · Sep 1, 2026
Spruce Biosciences · stocktitan.net · Aug 12, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Trevi Therapeutics · simplywall.st · Aug 1, 2026
Beta Bionics, Inc · stocktitan.net · Jul 24, 2026
nChroma Bio · altss.com · Jun 3, 2026
Click Therapeutics · finsmes.com · Apr 9, 2026
Alveus Therapeutics · finsmes.com · Mar 2, 2026
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Gossamer Bio | 11.0% | $16.00 | Feb 2019 | $111.3M |
| Bicara Therapeutics | 4.0% | $18.00 | Sep 2024 | $37.2M |
| Upstream Bio | 4.0% | $17.00 | Oct 2024 | $34.6M |
| Spruce Biosciences | 8.6% | $15.00 | Oct 2020 | $28.7M |
| Trevi Therapeutics | 4.4% | $10.00 | May 2019 | $7.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Nov 2024
Disclosed stake · filed Oct 2024
Disclosed stake · filed Feb 2022
Disclosed stake · filed Feb 2022
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2020
Disclosed stake · filed Feb 2020
Disclosed stake · filed Feb 2020
62 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Omega Funds made?
- Omega Funds has 46 tracked investments, 12 of which have exited, including 9 dated in the last 24 months.
- What stage does Omega Funds invest at?
- Omega Funds invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does Omega Funds focus on?
- Omega Funds focuses on Biotech, Medical Devices.
- Where is Omega Funds located?
- Omega Funds is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the team#OptimumTV meets Omega Funds Otello Stampacchia to discuss the #lifescience investor outlook on 2026
Optimum Strategic Communications · Otello Stampacchia
Extrait Conférences BIOTECH MEDTECH HEALTHTECH LeZoom19H : Vincent Ossipow, Partner chez Omega Funds
Biotech Finances · Vincent Ossipow
Co-investors · 21
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that make a meaningful difference in patients' lives.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Novartis Venture Fund is the corporate venture arm investing in life science companies, backing innovative drugs and treatments across various stages of growth.
SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.
Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university research and breakthrough science.
▶9 more co-investors
Frazier Healthcare PartnersvenBio PartnersPfizer Venture InvestmentsHatteras Venture PartnersRoche Venture FundAgent CapitalCanaan PartnersThe Column GroupCofounders Capital
Firms observed investing alongside Omega Funds, from public investor directories. Shared companies are the overlap with Omega Funds's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.